ClinicalTrials.gov
Cure8 trial brief
Wild Blueberries in Colitis
Diet and lifestyle
Microbiome
Colonoscopy
Fecal calprotectin
Flare
Fatigue
Phase 2 clinical trial
Adult patients
Why This Matters
This trial examines whether a blueberry-rich supplement can change inflammation, the microbiome, and intestinal barrier function in people with chronic colitis — topics many with IBD care about because diet and the microbiome may affect symptoms and disease activity.
Who Should Pay Attention
Adults with ulcerative colitis or Crohn’s colitis, patients interested in diet-based therapies, clinicians focused on nutritional/integrative care, and researchers studying microbiome–barrier interactions.
Study Snapshot
Story typeClinical Reference
Trial phaseNA
Enrollment60 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
The study enrolls inpatients at a German integrative medicine clinic and uses a crossover design so each participant spends 3 months on supplemental blueberry powder and 3 months without it.
Researchers collect colonoscopy (with confocal laser endomicroscopy) and optional sigmoidoscopy biopsies, blood, urine, stool and bile samples, questionnaires, and symptom/stool diaries at baseline, 12 and 24 weeks to examine microbiome, barrier integrity, inflammation, and patient-reported outcomes.
The trial pairs clinical sampling with ex vivo and molecular analyses to explore mechanisms linking blueberry components (polyphenols, anthocyanins, fiber) to microbiome and barrier effects. The intervention is dietary (about 35 g blueberry powder daily) added to an existing integrative inpatient program; it is not a drug trial.
Keep In Mind
The record is a registered interventional crossover trial recruiting at a single center and focuses on mechanistic outcomes (biopsies, molecular analyses) alongside patient-reported measures. As an exploratory study, findings would be preliminary and hypothesis-generating.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorUniversität Duisburg-Essen
Trial IDNCT06698601
Study typeInterventional
Trial phaseNA
Enrollment60 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedOct 1, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Understanding role of microbiota in Crohn's disease, ulcerative colitis
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
Protease Regulation and Impact of Sodium as Mechanisms of Inflammation in IBD
If sodium intake influences gut proteolytic activity, microbiota and inflammation, the findings could help tailor dietary guidance and personalized nutrition strategies for people with Crohn’s disease.
A very common vitamin has surprised scientists and is forcing them to rethink how to manage inflammation in Crohn’s disease and colitis
The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.